http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 06:46:33 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Starts+Turn+Therapeutics+%28TTRX%29+at+Buy/26786713.html <p>Ladenburg Thalmann initiates coverage on Turn Therapeutics (NASDAQ: TTRX) with a Buy rating and a price target of $26.00.</p><p>For an analyst ratings summary and ratings history on Turn Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=TTRX">click here</a>. For more ratings news on Turn Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TTRX&amp;type=analyst">click here</a>.</p><p>Shares of Turn Therapeutics closed at $9.12 yesterday.</p> http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Starts+Turn+Therapeutics+%28TTRX%29+at+Buy/26786713.html Mon, 20 Jul 2026 06:46:33 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jul+07/26738960.html si-local-file:///var/storage/secattach/20260707/26738960.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jul+07/26738960.html Tue, 07 Jul 2026 08:06:00 -0400 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html <p>Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial evaluating GX-03 for atopic dermatitis, resulting in an expanded and redesigned Stage 2 study protocol.</p> <p>The review, conducted under the oversight of an Independent Data Monitoring Committee, identified treatment activity in patients with baseline Eczema Area and Severity Index (EASI) scores of 1.1 to 7.0, a range generally considered mild-to-moderate disease. In that subgroup, GX-03 achieved Week 4 vIGA-AD Success in 71.4% of patients versus 33.3% on vehicle, and Week 8 complete disease clearance in 35.7% versus 11.1% on vehicle.</p> <p>The final http://www.streetinsider.com/FDA/Turn+Therapeutics+expands+GX-03+atopic+dermatitis+trial+scope/26738954.html Tue, 07 Jul 2026 08:05:19 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html <p class="bwalignc"> Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) </p><p class="bwalignc"> Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis </p><p class="bwalignc"> Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a single primary endpoint </p><p class="bwalignc"> Company http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+Announces+Final+Stage+2+Design+and+Data-Driven+Expansion+of+GX-03+Phase+2+Program+in+Atopic+Dermatitis/26738945.html Tue, 07 Jul 2026 08:05:00 -0400 A.06822034 A.36747586 O.00036564 O.20026344 TTRX http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+to+Host+Webcast+Presenting+Comprehensive+Interim+Analysis+and+Optimized+Stage+2+Design+for+GX-03+in+Atopic+Dermatitis/26735293.html <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the optimized Stage 2 study design that will guide completion of the Phase 2 program. </p><p> Following the preliminary interim assessment announced in June, the Company conducted a detailed multi-week http://www.streetinsider.com/Press+Releases/Turn+Therapeutics+to+Host+Webcast+Presenting+Comprehensive+Interim+Analysis+and+Optimized+Stage+2+Design+for+GX-03+in+Atopic+Dermatitis/26735293.html Mon, 06 Jul 2026 16:01:00 -0400 TTRX http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+to+Host+Webcast+Presenting+Comprehensive+Interim+Analysis+and+Optimized+Stage+2+Design+for+GX-03+in+Atopic+Dermatitis/26735293.html <p> WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the optimized Stage 2 study design that will guide completion of the Phase 2 program. </p><p> Following the preliminary interim assessment announced in June, the Company conducted a detailed multi-week http://www.streetinsider.com/Business+Wire/Turn+Therapeutics+to+Host+Webcast+Presenting+Comprehensive+Interim+Analysis+and+Optimized+Stage+2+Design+for+GX-03+in+Atopic+Dermatitis/26735293.html Mon, 06 Jul 2026 16:01:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Dewhurst+Martin+William/26618496.html si-local-file:///var/storage/secattach/20260608/26618496.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Dewhurst+Martin+William/26618496.html Mon, 08 Jun 2026 17:32:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Kester+Kent+Edward/26618484.html si-local-file:///var/storage/secattach/20260608/26618484.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Kester+Kent+Edward/26618484.html Mon, 08 Jun 2026 17:31:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+GOLDEN+ARTHUR+F/26618491.html si-local-file:///var/storage/secattach/20260608/26618491.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+GOLDEN+ARTHUR+F/26618491.html Mon, 08 Jun 2026 17:31:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Gengos+Andrew/26618492.html si-local-file:///var/storage/secattach/20260608/26618492.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+04++Filed+by%3A+Gengos+Andrew/26618492.html Mon, 08 Jun 2026 17:31:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+03/26594956.html si-local-file:///var/storage/secattach/20260603/26594956.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Turn+Therapeutics+Inc.++++For%3A+Jun+03/26594956.html Wed, 03 Jun 2026 06:13:00 -0400 TTRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+May+28++Filed+by%3A+BEB+Holdings%2C+LLC/26585417.html si-local-file:///var/storage/secattach/20260601/26585417.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Turn+Therapeutics+Inc.++++For%3A+May+28++Filed+by%3A+BEB+Holdings%2C+LLC/26585417.html Mon, 01 Jun 2026 18:07:00 -0400 TTRX